Avalon will attend the 30th Semi-Annual Diagnostic Coverage and Reimbursement Conference to participate in discussions focused on understanding fluctuations in Payer and LBM Policies, the incorporation of FDA oversight of LDTs into payment frameworks, the impact of state biomarker laws on organizational policy, the significance of breakthrough designation for commercial plans, and more.